Fig. 1From: Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging studyStudy design. IV, intravenous; PD, pharmacodynamics; PI, principal investigator; PK, pharmacokinetics; Q4W, every 4 weeks; TCZ, tocilizumabBack to article page